After primary EBV infection, individuals develop robust EBV-specific T cell immune responses, with EBV-specific CD8+ and some CD4+ T cells functioning as cytotoxic T cells, defending against the virus [27]. This evidence concerns the gene CD8A and Epstein-Barr virus infection.